Pathogenetic mechanisms of cardiac allograft vasculopathy--impact of nitric oxide
- PMID: 11151787
- DOI: 10.1007/s003920070022
Pathogenetic mechanisms of cardiac allograft vasculopathy--impact of nitric oxide
Abstract
In the cytokine-enriched environment of the chronically rejecting allograft, nitric oxide (NO) is predominantly produced by the inducible isoform of NOS synthase (NOS2) expressed by recipient-derived infiltrating immune cells as well as donor-derived vascular smooth muscle cells and endothelial cells. Early and persistent upregulation of NOS2 in allografts with cardiac allograft vasculopathy and downregulation of NOS2 coinciding with immunosuppressive attenuation of cardiac allograft vasculopathy have suggested NO as a regulator of cardiac allograft vasculopathy, the hallmark of chronic rejection. Pathogenetically, the development of cardiac allograft vasculopathy can be divided into an early phase, characterized by endothelial dysfunction, and a later phase, characterized by structural changes of vessel wall morphology. Several lines of evidence have shown that NO might play an essential role in both phases. Endothelial dysfunction due to immune-mediated injury of endothelial cells has been suggested as an early response-to-injury event in the pathogenesis of cardiac allograft vasculopathy. Functional studies in human transplant recipients have documented endothelial dysfunction of coronary artery vessels. Administration of L-arginine, the precursor of NO, improved endothelial function of both epicardial coronary arteries and coronary microvasculature indicating a protective effect of NO. To assess the impact of NO on the development of late structural changes, the severity of cardiac allograft vasculopathy was assessed in mice with targeted deletion of NOS2. A significant increase of vascular occlusion in NOS2-knockout mice demonstrated an antiarteriosclerotic effect of NOS2. In part, this effect could be explained by reduced neointimal smooth muscle cell accumulation after alloimmune injury. Taken together, NO plays an important role in maintaining vessel integrity after transplantation. Disruptions in NO pathways seem to play a key role in the progression from endothelial dysfunction to structural changes.
Similar articles
-
Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway.Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):567-75. doi: 10.1161/01.ATV.0000067060.31369.F9. Epub 2003 Mar 20. Arterioscler Thromb Vasc Biol. 2003. PMID: 12649081 Review.
-
Inhibiting the NO pathway with intracoronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation.J Heart Lung Transplant. 2003 Apr;22(4):439-51. doi: 10.1016/s1053-2498(02)00494-1. J Heart Lung Transplant. 2003. PMID: 12681422
-
Injury of the coronary endothelium at implantation increases endothelial dysfunction and intimal hyperplasia after heart transplantation.J Heart Lung Transplant. 2005 Mar;24(3):251-8. doi: 10.1016/j.healun.2003.12.012. J Heart Lung Transplant. 2005. PMID: 15737750
-
Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice.Circulation. 1998 May 26;97(20):2059-65. doi: 10.1161/01.cir.97.20.2059. Circulation. 1998. PMID: 9610537
-
Endothelial dysfunction and cardiac allograft vasculopathy.J Cardiovasc Transl Res. 2013 Apr;6(2):263-77. doi: 10.1007/s12265-012-9414-3. Epub 2012 Nov 8. J Cardiovasc Transl Res. 2013. PMID: 23135991 Review.
Cited by
-
N-Terminal-proBNP (NT-proBNP) as an indicator of cardiac dysfunction. A study in patients presenting with suspected cardiac disorders.Z Kardiol. 2005 Apr;94(4):247-54. doi: 10.1007/s00392-005-0205-6. Z Kardiol. 2005. PMID: 15803261 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical